Skip to main content

Table 2 Univariate and multivariate analysis of AML patients for overall survival

From: Low expression of ACLY associates with favorable prognosis in acute myeloid leukemia

Variables

Univariate analysis

Multivariate analysis

P value

HR (95% CI)

P value

HR (95% CI)

ACLY expression (high vs. low)

0.001

2.19 (1.38, 3.475)

0.029

1.805 (1.062, 3.068)

Age

< 0.001

1.007 (1.004, 1.011)

0.009

1.006 (1.001, 1.01)

WBC

< 0.001

1.005 (1.003, 1.007)

< 0.001

1.004 (1.002, 1.006)

Cytogenetic risks

 Intermediate vs. favorable

0.003

3.811 (1.556, 9.337)

0.027

3.748 (1.164, 12.069)

 Poor vs. favorable

< 0.001

8.539 (3.247, 22.454)

0.001

7.978 (2.34, 27.197)

Gene mutations (mutation vs. wild-type)

 FLT3-ITD

0.022

1.66(1.076, 2.56)

0.007

1.969(1.208,3.21)

 NPM1

0.051

1.434(0.998,2.061)

0.812

1.05(0.702,1.571)

 CEBPADM

0.022

0.385(0.169,0.874)

0.040

0.409(0.175,0.960)

 DNMT3A

0.001

2.474(1.483,4.125)

0.022

1.98(1.105,3.546)

Treatmenta

    

 HAA vs. DA

0.001

0.503 (0.335, 0.756)

0.007

0.536 (0.341, 0.842)

 IA vs. DA

0.003

0.567 (0.391, 0.824)

0.002

0.48 (0.304, 0.756)

  1. Age and WBC are taken as continuous variables
  2. WBC white blood cell, DM double-allele, CI confidence intervals, HR hazard ratio
  3. aThe treatment protocols are available from Table 1